Marinus Pharmaceuticals, Inc. provided revenue guidance for the fiscal year 2022. For the period, the company expects BARDA revenues in the range of $7 million to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | -1.48% |
|
-9.22% | -87.76% |
Jun. 17 | Sector Update: Health Care Stocks Decline Premarket Monday | MT |
Jun. 17 | Top Premarket Decliners | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.76% | 73.06M | |
+51.63% | 796B | |
+41.51% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.66% | 244B | |
+3.39% | 228B | |
+10.75% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Marinus Pharmaceuticals, Inc. Provides Revenue Guidance for the Fiscal Year 2022